论文部分内容阅读
Heart failure syndromes have significant impact on mortality and economic costs.Despite extensive research conducted,new drug agents are still required for heart failure treatment.Relaxin-2(relaxin)is a naturally occurring peptide hormone which recently passed Phase III clinical trials for the treatment of acute heart failure [1].It comprises of 2 chains(A-and Bchains)held together by three disulfide bonds and belongs to the relaxin peptide superfamily which interacts with a class of G-protein coupled receptors(GPCRs)referred to as the relaxin family peptide(RXFP)receptors [2].While relaxins cognate receptor is RXFP1,it can also bind to and activate the receptor for insulin-like peptide 3(INSL3),RXFP2.Signalling of this receptor is involved in regulating oocyte maturation,ovarian follicle development and ovary positioning.The use of a receptor-unselective human relaxin for clinical applications may impose undesired side effects via RXFP2-mediated physiological processes in patients.